Work

El Tratamiento Con El Anticuerpo Anti-proteoglicano Chp3r99 No Afecta La Bioenergética Mitocondrial En Ratones

Year: 2015
Type: article
Abstract: The proteoglycans are important biological molecules that participate in the retention of proatherogenic lipoproteins in the arterial wall, but also they are crucial for safe hepatic removal of atherogenic remnant lipoproteins from the circulation. Recently we obtained a monoclonal chimeric antibody named chP3R99 that reacts with sulfated molecules, including proteoglycans. Although the chemistry of low-density lipoprotein-proteoglycans interaction has been explored, the consequences of its inhibition by chP3R99 antibody on lipid metabolism and mitochondrial redox status have not been studied yet. Therefore, in the present work we characterized the liver mitochondrial function from C57BL6 mice subcutaneously treated with 50 µg of chP3R99 (weekly during 3 weeks). Hepatic mitochondria were isolated under standard procedures and their NAD(P)H status, susceptibility to permeability transition pore occurrence, and reactive oxygen production were assessed. On the other hand, the serum cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol were also determined. The results showed no significant changes of serum lipids levels among groups. The mitochondrial NAD(P)H status was no affected by chP3R99 treatment, neither mitochondrial permeability transition pore nor reactive oxygen species production were induced. Our results demonstrated that chP3R99 treatment does not interfere on lipid metabolism in normolipemic mice. Also, the lack of chP3R99 effect on the evaluated mitochondrial parameters demonstrated that the treatment with this antibody did not affect the hepatic mitochondrial redox status. Nevertheless, further toxicological studies should be performed to address the potential risks associated with the use of anti-proteoglycans immunotherapy.
Language: Spanish
Open Access status: diamond
OpenAlex ID: W2343583876
FWCI:
Cites: 35
Cited by:
Related to: 9